Coagulation factor VIII and von Willebrand factor complex (FVIII/VWF)

Coagulation factor VIII (FVIII) and von Willebrand factor (VWF) circulate as a non-covalent complex that is fundamental to the blood coagulation system (UniProt P00451, P04275). FVIII is a critical cofactor in the intrinsic pathway, accelerating the activation of Factor X by Factor IXa (StatPearls, Hemophilia A). VWF serves a dual purpose: it stabilizes FVIII, protecting it from rapid clearance and proteolytic degradation, and it facilitates platelet adhesion to damaged blood vessel walls by binding to subendothelial collagen and platelet receptors (StatPearls, von Willebrand Disease). Deficiencies in these proteins result in significant bleeding disorders, specifically Hemophilia A and von Willebrand disease. Therapeutic management often utilizes plasma-derived or recombinant FVIII/VWF complexes, such as Humate-P or Wilate, to replace the missing or defective proteins and restore hemostatic control (FDA, Humate-P Label). Clinical monitoring focuses on activity levels and the potential development of inhibitory antibodies that can compromise treatment efficacy.

Other names

Antihemophilic factor/von Willebrand factor complexFactor VIII/VWF complexFVIII-VWFFactor VIII/von Willebrand factor

The complex acts as replacement therapy where Factor VIII serves as a cofactor for Factor IXa in the activation of Factor X, while von Willebrand factor stabilizes Factor VIII and mediates platelet adhesion to the vascular subendothelium (StatPearls, 2023).